Intrahepatic cholangiocarcinoma research also benefits from PDX models, for instance, Huang et al used an intrahepatic cholangiocarcinoma PDX model to confirm the oncogenic role of YTHDF2 (YTH domain-containing family protein 2) and its contribution to cisplatin treatment desensitization.151. Here, YTHDF2 is linked to intrahepatic cholangiocarcinoma.